Boston Scientific ROA 2010-2024 | BSX
Current and historical return on assets (ROA) values for Boston Scientific (BSX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Boston Scientific ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2024-03-31 | $1.77B | $0.00B | 6.87% |
| 2023-12-31 | $1.57B | $35.14B | 4.63% |
| 2023-09-30 | $1.19B | $34.04B | 3.58% |
| 2023-06-30 | $0.86B | $33.60B | 2.63% |
| 2023-03-31 | $0.85B | $32.89B | 2.61% |
| 2022-12-31 | $0.64B | $32.47B | 1.99% |
| 2022-09-30 | $0.60B | $31.95B | 1.86% |
| 2022-06-30 | $0.83B | $32.19B | 2.58% |
| 2022-03-31 | $0.76B | $32.34B | 2.37% |
| 2021-12-31 | $0.99B | $32.23B | 3.12% |
| 2021-09-30 | $1.10B | $31.88B | 3.53% |
| 2021-06-30 | $0.53B | $31.17B | 1.70% |
| 2021-03-31 | $0.20B | $30.90B | 0.65% |
| 2020-12-31 | $-0.12B | $30.78B | -0.38% |
| 2020-09-30 | $3.69B | $30.85B | 12.05% |
| 2020-06-30 | $3.98B | $30.82B | 13.46% |
| 2020-03-31 | $4.29B | $30.11B | 15.35% |
| 2019-12-31 | $4.70B | $30.57B | 17.83% |
| 2019-09-30 | $1.09B | $26.76B | 4.55% |
| 2019-06-30 | $1.40B | $24.31B | 6.24% |
| 2019-03-31 | $1.80B | $23.80B | 8.48% |
| 2018-12-31 | $1.67B | $21.00B | 8.33% |
| 2018-09-30 | $0.67B | $20.38B | 3.43% |
| 2018-06-30 | $0.52B | $19.62B | 2.72% |
| 2018-03-31 | $0.11B | $19.20B | 0.60% |
| 2017-12-31 | $0.10B | $19.04B | 0.56% |
| 2017-09-30 | $0.84B | $18.64B | 4.62% |
| 2017-06-30 | $0.79B | $18.38B | 4.37% |
| 2017-03-31 | $0.44B | $17.94B | 2.43% |
| 2016-12-31 | $0.35B | $18.10B | 1.95% |
| 2016-09-30 | $0.08B | $17.70B | 0.45% |
| 2016-06-30 | $-0.35B | $17.84B | -1.92% |
| 2016-03-31 | $-0.04B | $17.72B | -0.20% |
| 2015-12-31 | $-0.24B | $18.13B | -1.37% |
| 2015-09-30 | $-0.40B | $18.22B | -2.30% |
| 2015-06-30 | $-0.16B | $17.12B | -0.92% |
| 2015-03-31 | $-0.25B | $16.47B | -1.52% |
| 2014-12-31 | $-0.12B | $17.02B | -0.72% |
| 2014-09-30 | $0.29B | $16.72B | 1.74% |
| 2014-06-30 | $0.24B | $16.48B | 1.45% |
| 2014-03-31 | $0.37B | $16.34B | 2.19% |
| 2013-12-31 | $-0.12B | $16.57B | -0.72% |
| 2013-09-30 | $-0.17B | $16.92B | -0.99% |
| 2013-06-30 | $-0.83B | $17.00B | -4.88% |
| 2013-03-31 | $-4.54B | $16.76B | -26.43% |
| 2012-12-31 | $-4.07B | $17.15B | -22.27% |
| 2012-09-30 | $-4.02B | $16.90B | -20.84% |
| 2012-06-30 | $-3.22B | $17.82B | -15.73% |
| 2012-03-31 | $0.51B | $21.19B | 2.38% |
| 2011-12-31 | $0.44B | $21.29B | 2.04% |
| 2011-09-30 | $0.57B | $21.50B | 2.61% |
| 2011-06-30 | $0.62B | $21.56B | 2.80% |
| 2011-03-31 | $0.57B | $22.07B | 2.54% |
| 2010-12-31 | $-1.07B | $22.13B | -4.71% |
| 2010-09-30 | $-2.38B | $22.49B | -10.17% |
| 2010-06-30 | $-2.66B | $23.02B | -10.94% |
| 2010-03-31 | $-2.60B | $22.85B | -10.36% |
| 2009-12-31 | $-1.03B | $25.18B | -3.95% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $107.347B | $14.240B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $186.584B | 24.49 |
| Stryker (SYK) | United States | $127.690B | 31.66 |
| Medtronic (MDT) | Ireland | $105.881B | 14.99 |
| EssilorLuxottica (ESLOY) | France | $98.566B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.036B | 0.00 |
| Haleon (HLN) | United Kingdom | $38.584B | 30.18 |
| ResMed (RMD) | United States | $32.074B | 30.08 |
| Terumo (TRUMY) | Japan | $24.746B | 34.95 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.522B | 15.79 |
| Baxter (BAX) | United States | $20.379B | 14.86 |
| Koninklijke Philips (PHG) | Netherlands | $19.567B | 15.61 |
| Insulet (PODD) | United States | $11.637B | 61.10 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.689B | 0.00 |
| Demant (WILYY) | Denmark | $9.943B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.869B | 23.44 |
| BellRing Brands (BRBR) | United States | $7.379B | 39.68 |
| Haemonetics (HAE) | United States | $4.621B | 23.63 |
| Lantheus Holdings (LNTH) | United States | $4.494B | 11.60 |
| Perrigo (PRGO) | Ireland | $4.328B | 12.38 |
| GN Store Nord (GNNDY) | Denmark | $4.065B | 26.32 |
| Envista Holdings (NVST) | United States | $3.504B | 13.33 |
| Prestige Consumer Healthcare (PBH) | United States | $3.499B | 16.54 |
| QuidelOrtho (QDEL) | United States | $2.651B | 9.62 |
| Neogen (NEOG) | United States | $2.630B | 25.29 |
| Green Thumb Industries (GTBIF) | United States | $2.571B | 81.47 |
| ICU Medical (ICUI) | United States | $2.311B | 17.24 |
| TG Therapeutics (TGTX) | United States | $2.082B | 673.50 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.936B | 0.00 |
| Owens & Minor (OMI) | United States | $1.922B | 18.45 |
| Agios Pharmaceuticals (AGIO) | United States | $1.770B | 0.00 |
| Verano Holdings (VRNOF) | United States | $1.697B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.469B | 48.49 |
| InMode (INMD) | Israel | $1.439B | 7.45 |
| National Vision Holdings (EYE) | United States | $1.400B | 43.61 |
| AdaptHealth (AHCO) | United States | $1.324B | 9.96 |
| Warby Parker (WRBY) | United States | $1.271B | 0.00 |
| AtriCure (ATRC) | United States | $1.121B | 0.00 |
| MacroGenics (MGNX) | United States | $0.911B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.893B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.794B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.709B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.682B | 14.73 |
| Evolus (EOLS) | United States | $0.662B | 0.00 |
| Jin Medical (ZJYL) | China | $0.626B | 0.00 |
| Quanterix (QTRX) | United States | $0.595B | 0.00 |
| Valneva SE (VALN) | France | $0.532B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.516B | 11.17 |
| PetIQ (PETQ) | United States | $0.486B | 18.16 |
| TerrAscend (TSNDF) | Canada | $0.486B | 0.00 |
| ZimVie (ZIMV) | United States | $0.431B | 26.37 |
| Biote (BTMD) | United States | $0.411B | 3.91 |
| OraSure Technologies (OSUR) | United States | $0.407B | 6.73 |
| Surmodics (SRDX) | United States | $0.373B | 40.26 |
| Aurora Cannabis (ACB) | Canada | $0.365B | 0.00 |
| Zynex (ZYXI) | United States | $0.361B | 41.52 |
| Viemed Healthcare (VMD) | United States | $0.322B | 31.96 |
| Cerus (CERS) | United States | $0.310B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.279B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.250B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.237B | 14.65 |
| Organigram Holdings (OGI) | Canada | $0.192B | 0.00 |
| Veru (VERU) | United States | $0.186B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.183B | 0.00 |
| Omeros (OMER) | United States | $0.183B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.170B | 0.00 |
| High Tide (HITI) | Canada | $0.161B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.156B | 0.00 |
| Eagleford Energy (GRUSF) | United States | $0.144B | 72.36 |
| FitLife Brands (FTLF) | United States | $0.132B | 21.28 |
| Jushi Holdings (JUSHF) | United States | $0.131B | 0.00 |
| InterCure (INCR) | Israel | $0.121B | 20.46 |
| Fonar (FONR) | United States | $0.103B | 8.84 |
| MariMed (MRMD) | United States | $0.100B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.100B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.098B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.092B | 0.00 |
| Safety Shot (SHOT) | United States | $0.082B | 0.00 |
| Chimerix (CMRX) | United States | $0.080B | 0.00 |
| Brainsway (BWAY) | Israel | $0.079B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.058B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.054B | 3.53 |
| Apyx Medical (APYX) | United States | $0.050B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.044B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.043B | 0.00 |
| ImmuCell (ICCC) | United States | $0.040B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 14.77 |
| Bright Green (BGXX) | United States | $0.038B | 0.00 |
| Modular Medical (MODD) | United States | $0.035B | 0.00 |
| Exagen (XGN) | United States | $0.024B | 0.00 |
| Nephros (NEPH) | United States | $0.023B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.019B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.017B | 0.00 |
| Agape ATP (ATPC) | $0.017B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.012B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.010B | 71.82 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.003B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.001B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |